

Clinical Oversight Review Board (CORB) Criteria for Prescribing/
Criteria-Based Consultation (CBC) Criteria for Coverage

Coagulation Factor IX (Rebinyn)

Non-Formulary **coagulation Factor IX (Rebinyn)** requires a clinical review.
Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria: Non-formulary **Coagulation Factor IX (Rebinyn)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by Hematology/Oncology provider
- Patient has diagnosis of hemophilia B
- Documented treatment failure or intolerance to:
 - Benefix -OR- Rixubis
 - AND-**
 - Alprolix -OR- Idelvion
- Used perioperatively for management of bleeding -OR- to control an acute bleeding episode